HUTCHMED (China) (HMDCF) Non-Current Deffered Revenue (2015 - 2026)
HUTCHMED (China)'s (HMDCF) quarterly Non-Current Deffered Revenue came in at $10.6 million in Q2 2026, down 65.64% year-over-year from $30.8 million in Q2 2025, and down 47.46% quarter-over-quarter from $20.1 million in Q4 2025.
Analysis
HUTCHMED (China) (HMDCF) Non-Current Deffered Revenue (2015 - 2026) Analysis & Trends
HUTCHMED (China) (HMDCF) has reported Non-Current Deffered Revenue for 11 consecutive years, with $10.6 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Non-Current Deffered Revenue fell 65.64% year-over-year to $10.6 million in Q2 2026; TTM through Jun 2026 was $10.6 million, a 65.64% decrease from a year earlier, with the FY2025 full-year figure at $20.1 million, changed N/A from the prior year.
- Non-Current Deffered Revenue was $10.6 million for Q2 2026 at HUTCHMED (China), down from $20.1 million in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $97.2 million in Q2 2023 and troughed at $190000.0 in Q4 2022.
- A 5-year average of $36.6 million and a median of $25.5 million in 2025 frame the typical range for Non-Current Deffered Revenue.
- Across the five-year window, Non-Current Deffered Revenue tumbled 37.61% in 2024 and tumbled 65.64% in 2026, its largest moves.
- Over 5 years, Non-Current Deffered Revenue stood at $190000.0 in 2022, then surged by 51045.26% to $97.2 million in 2023, then tumbled by 37.61% to $60.6 million in 2024, then sank by 66.79% to $20.1 million in 2025, then slumped by 47.46% to $10.6 million in 2026.
- The last three Non-Current Deffered Revenue figures came in at $10.6 million (Q2 2026), $20.1 million (Q4 2025), and $30.8 million (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.50 Bn | 197.51 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 181.29 Bn | 178.11 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.55 Bn | 74.56 Bn | 3.93 Bn | 220.40 Mn |
| 5 | Argenx Se | 61.65 Bn | 56.47 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.65 Bn | 49.52 Bn | 52.00 Mn | 147.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.18 Bn | 30.87 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.36 Bn | 30.07 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.01 Bn | 30.01 Bn | 1.16 Mn | - |
| 10 | HUTCHMED (China) | 376.85 Mn | 391.04 Mn | - | 10.58 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 10.58 Mn |
| Dec 31, 2025 | 20.13 Mn |
| Jun 30, 2025 | 30.79 Mn |
| Jun 30, 2024 | 60.63 Mn |
| Jun 30, 2023 | 97.18 Mn |
| Dec 31, 2022 | 190,000.00 |
| Dec 31, 2020 | 484,000.00 |
| Dec 31, 2019 | 133,000.00 |
| Dec 31, 2018 | 408,000.00 |
| Jun 30, 2018 | 924,000.00 |
| Dec 31, 2017 | 1.99 Mn |
| Dec 31, 2016 | 2.26 Mn |
| Dec 31, 2015 | 2.13 Mn |